1212 related articles for article (PubMed ID: 16449979)
1. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
Bigelow RL; Cardelli JA
Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
[TBL] [Abstract][Full Text] [Related]
2. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
[TBL] [Abstract][Full Text] [Related]
3. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells.
Duhon D; Bigelow RL; Coleman DT; Steffan JJ; Yu C; Langston W; Kevil CG; Cardelli JA
Mol Carcinog; 2010 Aug; 49(8):739-49. PubMed ID: 20623641
[TBL] [Abstract][Full Text] [Related]
4. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells.
Lim YC; Park HY; Hwang HS; Kang SU; Pyun JH; Lee MH; Choi EC; Kim CH
Cancer Lett; 2008 Nov; 271(1):140-52. PubMed ID: 18632202
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved.
Chung JY; Huang C; Meng X; Dong Z; Yang CS
Cancer Res; 1999 Sep; 59(18):4610-7. PubMed ID: 10493515
[TBL] [Abstract][Full Text] [Related]
6. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
7. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
8. Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549.
Yamauchi R; Sasaki K; Yoshida K
Toxicol In Vitro; 2009 Aug; 23(5):834-9. PubMed ID: 19406223
[TBL] [Abstract][Full Text] [Related]
9. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.
Jung YD; Kim MS; Shin BA; Chay KO; Ahn BW; Liu W; Bucana CD; Gallick GE; Ellis LM
Br J Cancer; 2001 Mar; 84(6):844-50. PubMed ID: 11259102
[TBL] [Abstract][Full Text] [Related]
10. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
11. The green tea compound, (-)-epigallocatechin-3-gallate downregulates N-cadherin and suppresses migration of bladder carcinoma cells.
Rieger-Christ KM; Hanley R; Lodowsky C; Bernier T; Vemulapalli P; Roth M; Kim J; Yee AS; Le SM; Marie PJ; Libertino JA; Summerhayes IC
J Cell Biochem; 2007 Oct; 102(2):377-88. PubMed ID: 17348027
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Masuda M; Suzui M; Lim JT; Weinstein IB
Clin Cancer Res; 2003 Aug; 9(9):3486-91. PubMed ID: 12960141
[TBL] [Abstract][Full Text] [Related]
13. Tea polyphenols inhibit IL-6 production in tumor necrosis factor superfamily 14-stimulated human gingival fibroblasts.
Hosokawa Y; Hosokawa I; Ozaki K; Nakanishi T; Nakae H; Matsuo T
Mol Nutr Food Res; 2010 Jul; 54 Suppl 2():S151-8. PubMed ID: 20461739
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
[TBL] [Abstract][Full Text] [Related]
15. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells.
Kim M; Murakami A; Kawabata K; Ohigashi H
Carcinogenesis; 2005 Sep; 26(9):1553-62. PubMed ID: 15860507
[TBL] [Abstract][Full Text] [Related]
17. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the bitterness of green tea catechins by a cell-based assay with the human bitter taste receptor hTAS2R39.
Narukawa M; Noga C; Ueno Y; Sato T; Misaka T; Watanabe T
Biochem Biophys Res Commun; 2011 Feb; 405(4):620-5. PubMed ID: 21272567
[TBL] [Abstract][Full Text] [Related]
20. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways.
Leibowitz-Amit R; Tsarfaty G; Abargil Y; Yerushalmi GM; Horev J; Tsarfaty I
Cancer Res; 2006 Sep; 66(17):8687-97. PubMed ID: 16951184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]